Sensyne Health PLC Agreement with NHS Greater Glasgow and Clyde (8455A)

TIDMSENS

RNS Number : 8455A

Sensyne Health PLC

01 October 2020

Sensyne Health and NHS Greater Glasgow and Clyde sign data access agreement

Oxford, U.K. 1 October 2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces it has signed a non-exclusive data sharing agreement with NHS Greater Glasgow and Clyde ("NHSGGC") giving Sensyne access to three separate anonymised patient data sets in three specific disease areas including cardiovascular disease.

The anonymised patient data will be used by Sensyne to undertake medical research using Clinical AI, improve pharmaceutical development and help deliver better patient care.

NHSGGC is one of 14 regional NHS Boards in Scotland. It serves a population of 1.14 million and employs around 39,000 staff. It is the largest NHS organisation in Scotland and one of the largest in the UK including 35 Hospitals of different types.

The agreement falls under the Glasgow Safe Haven partnership between NHS Greater Glasgow and Clyde and the University of Glasgow, designed to provide secure access to NHS and other health datasets derived from diverse sources across the health service. The Glasgow Safe Haven is accredited by the Scottish Government as an accredited Safe Haven, and is one of four regional Safe Havens across Scotland. By enabling researchers to link data from different sources, Safe Havens encourage data-driven health research to improve health services, design better treatments, and to create innovative new health products to support better health in Scotland.

Prof Julie Brittenden, Director of Research and Innovation, NHS Greater Glasgow and Clyde, said:

"We are pleased to collaborate with Sensyne on data-driven approaches which aim to ultimately improve early diagnosis and treatment of various illnesses, including cardiovascular disease. The project will use anonymised patient data within the secure Glasgow Safehaven to test Sensyne's machine learning models. This is one of many of our collaborations with industry to improve research and development in order to benefit our patients in future."

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"We are delighted to be working with one of the largest NHS Boards in Scotland on data analysis to improve patient care and accelerate medical research. Adding this data sharing agreement to our Strategic Research Agreements expands our access to anonymised patient data to now cover 3.9 million patients."

-ENDS-

For more information please contact:

 
  Sensyne Health ( www.sensynehealth.com             [phone] 
   )                                                  1845 
  Lord (Paul) Drayson PhD FREng, Chief Executive 
   Officer 
  Michael Norris, Interim Chief Financial 
   Officer 
 
    Peel Hunt LLP (Nominated Adviser and Joint         + 44 (0) 20 7418 
    Broker)                                            8900 
  Dr Christopher Golden 
  James Steel 
  Oliver Jackson 
                                                     + 44 (0) 20 3100 
  Liberum (Joint Broker)                              2000 
  Bidhi Bhoma 
  Euan Brown 
                                                     [phone] 
  Consilium Strategic Communications                  8207 
  Mary-Jane Elliott 
  Sukaina Virji 
  Melissa Gardiner 
  CSCS [e-mail] 
 

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRFSAFEFESSEIS

(END) Dow Jones Newswires

October 01, 2020 09:00 ET (13:00 GMT)